Skip to main content
. 2021 Feb 20;9(4):1905–1912. doi: 10.1002/ccr3.3900

FIGURE 4.

FIGURE 4

After 4 weeks on larotrectinib treatment, an 18F‐FDG PET/CT scan showed a near‐complete response—only neck lymph node and lung (arrowed) lesions persisted in October 2019 after 4 weeks of larotrectinib (200 mg/day) treatment (transverse view); most lesions had disappeared. 18 F‐FDG, 2‐deoxy‐2‐[fluorine‐18] fluoro‐D‐glucose; PET/CT, positron emission tomography/computed tomography